Tricida Ready For FDA Filing With Long-Term Safety, Efficacy Data In CKD
Executive Summary
Not only did Tricida’s Phase III long-term extension study show safety for TRC101 in CKD metabolic acidosis patients, but also promise in renal health outcomes. Biomedtracker voiced caution on those findings, though, due to study limitations.
You may also be interested in...
Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results
Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.
IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year
Nearly two-thirds of the 67 drug developers that launched an IPO in 2018 were trading below their offering price at the end of the year, bringing the average return to -7.5%. Even so, biopharma companies continue to line up for a US stock market debut.